

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

Applicant
Coller et al.

ATTACH TO #8

Filing Date
May 15, 2001

Group
1624

RECEIVED

JUL 18 2002

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
6.	5 7 5 3 2 3 0	05/19/98	Brooks et al.	—	—	
7.	5 7 8 0 4 2 6	07/14/98	Palladino et al	—	—	
23.	5 4 4 0 0 2 0	08/08/95	Coller	—	—	
27.	5 3 8 7 4 1 3	02/07/95	Coller	—	—	
57.	4 4 7 4 8 9 3	10/02/84	Reading	—	—	

FOREIGN PATENT DOCUMENT

Document No.	Date	Country	Class	SubClass	Translation Yes No
26. 9 5 1 2 4 1 2	05/11/95	WIPO	—	—	

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

*1.	Fundamental Immunology, Paul W.E. ed., 4th Edition, 1999. Lippincott Williams & Wilkins Publishers, p. 242.
*2.	Varner JA, Nakada MT, Jordan RE, Coller BS (1999). Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro™). Angiogenesis 3:53-60.
*3.	Arap W, Pasqualini R, Ruoslahti E (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377-380.
4.	Bombeli T, Schwartz BR, Harlan JM (1998). Adhesion of activated platelets to endothelial cells: evidence for a GPIIb/IIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), $\alpha_v\beta_3$ integrin, and GPIb α . J. Exp. Med. 187(3):329-339.
*5.	Tam SH, Sassoli PM, Jordan RE, Nakada MT (1998). Abciximab (ReoPro, Chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and $\alpha_v\beta_3$ integrins. Circulation 1998 Sep 15;98(11):1085-1091.
*8.	Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, Huse WD, Watkins JD (1998). Stepwise in vitro affinity maturation of Vitaxin, an $\alpha_v\beta_3$ -specific humanized mAb. Proc. Natl. Acad. Sci. USA 95(11):6037-

Examiner

Date Considered

12/30/02

Atty. Docket No.
A31386-A (070165.0593)

Serial No.
09/855,886

Applicant
Coller et al.

Filing Date
May 15, 2001

Group
1624

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

TECH CENTER 1600/2900

JUL 18 2002

RECEIVED

LA	9.	✓	Coller BS (1997). Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. Perspectives Series: Cell Adhesion in Vascular Biology. J. Clin. Invest. (Suppl.) 100 (11):S57-S60.
	*10.		Nakada MT, Jordan RE, Knight DM (1997). Abciximab (ReoPro, chimeric 7E3 Fab) cross-specificity with $\alpha_v\beta_3$ integrin receptors: a potential mechanism for the prevention of restenosis " J. Amer. Coll. Cardiol. 29(2):243A (abstract).
	*11.		Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997). Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20):4593-4599.
	*12.		Taylor FB, Coller BS, Chang AC, Peer G, Jordan R, Engellener W, Esmon CT (1997). 7E3 F(ab') ₂ monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated With C4b binding protein and a sublethal infusion of <i>Escherichia coli</i> . Blood 89(11): 4078-4084.
	*13.		Varner JA (1997). The role of vascular cell integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ in angiogenesis. In: Regulation of Angiogenesis, Goldberg and Rosen, eds., Basel: Birkheuser Verlag, Volume 79, pp. 361-390.
	*14.		Varner JA, Nakada M, Jordan M, Coller B (1997). Anti-angiogenic properties of 7E3, an integrin β_3 subunit antagonist, in the SCID mouse-human skin model of human angiogenesis. Thromb. Haemost. 77 (Suppl.):158 (abstract PD-645) (Abstracts presented June 6-12, 1997 at the 15th meeting in Florence, Italy).
	15.		O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
	*16.		Coller BS, Anderson KM, Weisman HF (1996). The anti-GPIIb-IIIa agents: fundamental and clinical aspects. Haemostasis 26 (Suppl 4):285-293.
	*17.		Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresch DA (1996). Involvement of integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA 93(18):9764-9769.
	*18.		Marcinkiewicz C, Rosenthal LA, Mosser DM, Kunicki TJ, Niewiarowski S (1996). Immunological characterization of ristostatin and echistatin binding sites on $\alpha_{IIb}\beta_3$ and $\alpha_v\beta_3$ integrins. Biochem. J. 317:817-825.
	*19.		Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS (1996). Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J. Clin. Invest. 98:863-874.
	*20.		Varner JA, Cheresch DA (1996). Integrins and cancer. Curr. Opin. Cell. Biol. 8(5):724-730.
	*21.		Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresch DA (1995). Definition of two angiogenic pathways by distinct α_v integrins. Science 270:1500-1502.
LA	*22.		Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresch DA (1995). Antiintegrin $\alpha_v\beta_3$ blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96:1815-1822.

Examiner

Date Considered

12/30/02

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
A31386-A (070165.0593)

Serial No.
09/855,886

Applicant
Coller et al.

Filing Date
May 15, 2001

Group
1624

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

RECEIVED
JUL 18 2002
TECH CENTER 1600/2900

24.		Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ (1995). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. <i>Hum. Pathol.</i> <u>26</u> (1):86-91.
25.		Hatva E, Kaipainen A, Mentula P, Jaaskelainen J, Paetau A, Haltia M, Alitalo K (1995). Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. <i>Amer. J. Pathol.</i> <u>146</u> (2):368-378.
*28.	/	Brooks PC, Clark RA, Cheresh DA (1994). Requirement of vascular integrin $\alpha_v\beta_3$ for angiogenesis. <i>Science</i> <u>264</u> :569-571.
*29.		Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994). Integrin $\alpha_v\beta_3$ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. <i>Cell</i> <u>79</u> :1157-1164.
30.	/	Coller BS, Seligsohn U, Peretz H, Newman PJ (1994). Glanzmann thrombasthenia: new insights from an historical perspective. <i>Semin Hematol</i> <u>31</u> (4):301-311.
31.	/	DeLisser HM, Newman PJ, Albelda SM (1994). Molecular and functional aspects of PECAM-1/CD31. <i>Immunol. Today</i> <u>15</u> (10):490-495.
32.	/	Leek RD, Harris AL, Lewis CE (1994). Cytokine networks in solid human tumors: regulation of angiogenesis. <i>J. Leukoc. Biol.</i> <u>56</u> :423-435.
33.	/	O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases. <i>Cell</i> <u>79</u> :315-328.
*34.	/	Seaver S. Genetic Engineering News, August 10, 1994, Volume 14, pp. 10 and 21.
*35.	/	Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, <i>et al.</i> (1994). Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. <i>Lancet</i> <u>343</u> (8902):881-886.
36.	/	Vartanian RK, Weidner N (1994). Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. <i>Am. J. Pathol.</i> <u>144</u> (6):1188-1194.
37.	/	Weinstat-Saslow D, Steeg PS (1994). Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. <i>FASEB J</i> <u>8</u> :401-407.
38.	/	Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR (1993). Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. <i>Amer. J. Path.</i> <u>143</u> :1255-1262
39.	/	Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA (1992). Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. <i>J. Clin. Invest.</i> <u>89</u> (6):2018-2022.
40.	/	Folkman J (1992). The role of angiogenesis in tumor growth. <i>Sem. Cancer Biol.</i> <u>3</u> :65-71.

Examiner

Date Considered

12/30/02

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.
A31386-A (070165.0593)

Serial No.
09/855,886

Applicant
Coller et al.

Filing Date
May 15, 2001

Group
1624

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

RECEIVED
JUL 18 2002
TECH CENTER 1600/2900

41.	Plate KH, Breier G, Weich HA, Risau W (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas <i>in vivo</i> . Nature <u>359</u> :845-848.
*42.	Wayner EA, Orlando RA, Cheresch DA (1991). Integrins $\alpha_v\beta_3$ contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J. Cell Biol. <u>113</u> :919-929.
43.	Liotta LA, Steeg PS, Stetler-Stevenson WG (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell <u>64</u> :327-336.
44.	Weidner N, Semple JP, Welch WR, Folkman J (1991). Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl. J. Med. <u>324</u> :1-8.
*45.	Coller BS, Cheresch DA, Asch E, Seligsohn U (1991). Platelet vitronectin receptor expression differentiates Iraqi-Jewish From Arab patients with Glanzmann thrombasthenia in Israel. Blood <u>77</u> :75-83.
46.	Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H (1991). Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann. NY Acad. Sci. <u>614</u> :193-213.
*47.	Bowie JU, Reidhaar-Olson JF, Lim WA, Sauer RT (1990). Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science <u>247</u> (4948):1306-1310.
48.	Blood CH, Zetter BR (1990). Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta <u>1032</u> :89-118.
*49.	Burgess WH, Shaheen AM, Ravera M, Jaye M, Donohue PJ, Winkles JA (1990). Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. J. Cell Biol. <u>111</u> (5 Pt 1):2129-2138.
*50.	Lazar E, Vicenzi E, Van Obberghen-Schilling E, Wolff B, Dalton S, Watanabe S, Sporn MB (1989). Transforming growth factor alpha: an aromatic side chain at position 38 is essential for biological activity. Mol. Cell Biol. <u>9</u> (2):860-864.
*51.	Tao MH, Morrison SL (1989). Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. <u>143</u> (8):2595-2601.
*52.	Karpatkin S, Pearlstein E, Ambrogio C, Coller BS (1988). Role of adhesive proteins in platelet tumor Interactions in vitro and metasasis formation in vivo. J. Clin. Invest. <u>81</u> : 1012-1019.
53.	Folkman J, Klagsbrun M (1987). Angiogenic factors. Science <u>235</u> :442-447.
54.	Cheresch DA (1987). Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc. Natl. Acad. Sci. U.S.A. <u>84</u> :6471-6475.
*55.	Coller BS (1986). Activation affects access to the platelet receptor for adhesive glycoproteins. J. Cell. Biol. <u>103</u> :451-456.

Examiner

Date Considered

12/30/02

Atty. Docket No.
A31386-A (070165.0593)

Serial No.
09/855,886

Applicant
Coller et al.

Filing Date
May 15, 2001

Group
1624

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

RECEIVED
JUL 18 2002
TECH CENTER 1600/2900

56.	Coller BS (1985). A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J. Clin. Invest. <u>76</u> :101-108.
58.	Coller BS, Peerschke EI, Scudder LE, Sullivan CA (1983). A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest. <u>72</u> :325-338.
59.	<i>Harrison's Principles of Internal Medicine</i> . Petersdorf <i>et al.</i> , eds. 10th Edition, 1983. McGraw-Hill Professional Publishing. pp. 1868-1869.
60.	Levy R, Dilley J, Lampson LA (1978). Human normal and leukemia cell surface antigens. Mouse monoclonal antibodies as probes. Curr. Top. Microbiol. Immunol. <u>81</u> :164-169.
61.	Sevier ED, David GS, Martinis J, Desmond WJ, Bartholomew RM, Wang R (1981). Monoclonal antibodies in clinical immunology. Clin. Chem. <u>27</u> (11):1797-1806.

Examiner

Date Considered

12/30/02

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.